Log in

AgeX Therapeutics Stock Price, News & Analysis (NYSE:AGE)

+0.11 (+6.92 %)
(As of 10/22/2019 02:20 AM ET)
Today's Range
Now: $1.70
50-Day Range
MA: $2.12
52-Week Range
Now: $1.70
Volume58,800 shs
Average Volume82,107 shs
Market Capitalization$63.97 million
P/E RatioN/A
Dividend YieldN/A
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues. It is also involved in the development of AGEX-iTR1547, a drug-based formulation in preclinical development for restoring regenerative potential in various aged tissues afflicted with degenerative diseases. In addition, the company develops Renelon, a first-generation tissue regeneration product designed to promote scarless tissue repair. Further, it markets genomic interpretation algorithms; and Cytiva, including pluripotent stem cell derived heart muscle cells used in screening drugs for efficacy and safety. The company was founded in 2017 and is based in Alameda, California. AgeX Therapeutics, Inc.(AMEX:AGE) operates independently of BioTime, Inc. as of November 28, 2018.

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$1.40 million
Book Value$0.23 per share



Market Cap$63.97 million
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable

Receive AGE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGE and its competitors with MarketBeat's FREE daily newsletter.

AgeX Therapeutics (NYSE:AGE) Frequently Asked Questions

What is AgeX Therapeutics' stock symbol?

AgeX Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGE."

How were AgeX Therapeutics' earnings last quarter?

AgeX Therapeutics (NYSE:AGE) posted its earnings results on Wednesday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The company earned $0.38 million during the quarter. View AgeX Therapeutics' Earnings History.

When is AgeX Therapeutics' next earnings date?

AgeX Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for AgeX Therapeutics.

Has AgeX Therapeutics been receiving favorable news coverage?

News coverage about AGE stock has been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AgeX Therapeutics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for AgeX Therapeutics.

Who are some of AgeX Therapeutics' key competitors?

What other stocks do shareholders of AgeX Therapeutics own?

Who are AgeX Therapeutics' key executives?

AgeX Therapeutics' management team includes the folowing people:
  • Mr. Alfred D. Kingsley, Exec. Chairman (Age 75)
  • Dr. Michael D. West, Pres, CEO & Director (Age 65)
  • Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
  • Mr. Nafees Naseer Malik, Chief Operating Officer
  • Dr. Aubrey D. N. J. de Grey BA, MA,Ph.D., Vice-Pres of New Technology Discovery

Who are AgeX Therapeutics' major shareholders?

AgeX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Defender Capital LLC. (0.55%). View Institutional Ownership Trends for AgeX Therapeutics.

Which major investors are selling AgeX Therapeutics stock?

AGE stock was sold by a variety of institutional investors in the last quarter, including Defender Capital LLC.. View Insider Buying and Selling for AgeX Therapeutics.

How do I buy shares of AgeX Therapeutics?

Shares of AGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AgeX Therapeutics' stock price today?

One share of AGE stock can currently be purchased for approximately $1.70.

How big of a company is AgeX Therapeutics?

AgeX Therapeutics has a market capitalization of $63.97 million and generates $1.40 million in revenue each year. View Additional Information About AgeX Therapeutics.

What is AgeX Therapeutics' official website?

The official website for AgeX Therapeutics is http://www.agexinc.com/.

How can I contact AgeX Therapeutics?

AgeX Therapeutics' mailing address is 1010 ATLANTIC AVENUE SUITE 102, ALAMEDA CA, 94501. The company can be reached via phone at 510-871-4190.

MarketBeat Community Rating for AgeX Therapeutics (NYSE AGE)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  32 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  76
MarketBeat's community ratings are surveys of what our community members think about AgeX Therapeutics and other stocks. Vote "Outperform" if you believe AGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: What causes a recession?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel